Remus Pharmaceuticals Limited — PPTs, 15-11-2024: Investor Presentation

**Financial Highlights:**

For H1 FY 2025, Remus Pharmaceuticals reported consolidated total revenue of ₹27,555.54 lakhs, reflecting an increase from ₹30,69.90 lakhs in H1 FY 2024. Consolidated PAT surged to ₹1,401.12 lakhs, up from ₹564.76 lakhs in the prior year. Standalone revenue also rose to ₹4,021.23 lakhs, while PAT improved to ₹955.29 lakhs. Notable financial metrics include a consolidated ROCE of 44.92% and an ROE of 34.77%.

**Strategic Initiatives and Growth Drivers:**

Remus has been expanding its presence in Latin America, CIS, and Southeast Asia with over 580 registered products and ambitions for 2,000 new filings within three years. The launch of 50 new products in Bolivia and entry into new markets like El Salvador and Peru highlight the growth-focused strategy.

**Business Developments:**

The company secured significant tenders, particularly in oncology and orphan drugs, and has begun business initiatives in Saudi Arabia, with multiple filings in progress. In Eastern Europe, it submitted dossiers to enhance market positioning.

**Market Position and Competitive Advantage:**

Remus focuses on strong branding and regulatory compliance across multiple markets, ensuring safety and efficacy for a diverse product portfolio. Strategic partnerships further enable access to government and institutional tenders.

**Investor Implications:**

With robust growth in revenues and strategic market expansions, Remus appears poised for substantial future growth. Investors should monitor the execution of its market entry strategies and product launches in emerging markets for potential upside.